Merck and Moderna's Melanoma Vaccine Posts Positive Phase 3 Results

Merck and Moderna have announced positive Phase 3 results for their personalized mRNA-based melanoma vaccine, intismeran autogene. The treatment, combined with Merck's immunotherapy Keytruda, significantly extended the time before cancer returned in patients whose high-risk melanoma had been surgically removed.

The randomized trial, INTerpath-001, enrolled 1,137 patients with completely resected stage IIB-IV cutaneous melanoma. The combination met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, with results described as statistically significant and clinically meaningful.

Mexico's Ministry of Health has moved to shorten the regulatory pathway for trials involving complex therapies like personalized cancer vaccines. COFEPRIS has cut clinical trial approval timelines from 120 to 30 days, a shift that Minister of Health David Kershenobich linked to efforts to increase Mexico's participation in international oncology studies.

The result also reinforces the broader commercial case for mRNA technology beyond infectious disease. Analysts estimate an approved product could generate more than US$6 billion in annual sales in melanoma alone, with additional potential should the platform prove effective against lung, kidney, and bladder cancers.